Company
Headquarters: Guangzhou, China
Employees: 3,326
CEO: Mr. Yonghui Wang
CN¥5.53 Billion
CNY as of July 1, 2025
US$772.6 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. The company was founded in 1997 and is based in Guangzhou, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥1.71 B |
| EBITDA | CN¥22.7 M |
| Gross Profit TTM | CN¥327.2 M |
| Profit Margin | -53.23% |
| Operating Margin | -0.74% |
| Quarterly Revenue Growth | -26.00% |
Xiangxue Pharmaceutical Co.,Ltd. has the following listings and related stock indices.
Stock: SZSE: 300147 wb_incandescent